Key Highlights: Implications: Extensior catapults Abbott into the GLP-1 frenzy, grabbing prime shelf space before generics from Eris/Natco crash prices by half—think explosive Tier-2 growt...
Key Highlights: Implications: Pharma innovators breathe easy as testing bottlenecks vanish, unleashing faster launches for complex biologics and nephrology breakthroughs. Local manufa...
Key Highlights: Implications: MSN joins the generics stampede, slashing premium GLP-1 prices and handing endocrinologists budget-friendly options for mass diabetes management.&n...
Key Highlights: Implications: Oncology ace Vanneste turbocharges MSD’s immuno-oncology push against Roche/Pfizer, targeting India’s exploding cancer caseload with ke...
Key Highlights: Implications: Nubeqa’s India approval intensifies mHSPC competition against Janssen’s Erleada, amid prostate therapeutics market growing at 8.2% CAGR to $739M by 2030. ...
Key Highlights: Implications: Survey hands GSK potent ammo to ignite shingles vaccination drives targeting CKD/diabetes clinics where patient disruption peaks. Chronic disease n...
Key Highlights: Implications: Zydus’ smart-pen assault smashes generic pricing barriers, handing endocrinologists flexible dosing that trumps competitor pens while exploding Tier-2 a...
Key Highlights: Implications: Semaglutide generics could slash Novo Nordisk pricing by 70-80% in India’s $2.5B diabetes market (12% CAGR), capturing 25%+ share and pressuring chronic...
Key Highlights: Implications: StopBleed fills critical gap in India’s trauma response, handing emergency teams a game-changing tool that slashes preventable bleeding death...
Key Highlights: Implication: This divestment signals multinational pharma firms accelerating exits from legacy India operations, potentially pressuring peers like Roche and Sanofi to restructure...